Eli Lilly's antibody drug bamlanivimab was found to "significantly" reduce the risk of contracting symptomatic COVID-19 in nursing homes, the company has announced.
Eli Lilly said Thursday a phase 3 trial showed that nursing home residents who preventively received bamlanivimab rather than a placebo had an up to 80 percent lower risk of contracting symptomatic COVID-19. Additionally, the company said bamlanivimab reduced the risk by 57 percent for both residents and staff, The Wall Street Journal reports.
"We are exceptionally pleased with these positive results, which showed bamlanivimab was able to help prevent COVID-19, substantially reducing symptomatic disease among nursing home residents, some of the most vulnerable members of our society," Eli Lilly chief scientific officer Daniel Skovronsky said.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Skovronsky further explained in an interview with the Journal that the company's antibody treatment is "not an alternative for a vaccine," but "for people who haven't been vaccinated, and there's an outbreak in their facility — this could be a last resort." In Eli Lilly's announcement, Skovronsky said that after the Food and Drug Administration previously provided an emergency use authorization for bamlanivimab, the company hopes to work "with regulators to explore expanding the emergency use authorization to prevent the spread of COVID-19 in these facilities."
-
August 17 editorial cartoonsCartoons Sunday’s political cartoons include voting rights of felons, misdirection on the way to the Alaska summit, and more
-
5 crime-ridden cartoons about National Guard deployment in DCCartoons Artists take on the crime of littering, the real criminals in DC, and more
-
Trump and Modi: the end of a beautiful friendship?In the Spotlight Harsh US tariffs designed to wrest concessions from Delhi have been condemned as 'a new form of imperialism'
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panelspeed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sickspeed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last yearspeed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive orderspeed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
